IN RE: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation

  1. January 25, 2018

    Allergan, Restasis Buyers Can't Agree On MDL Venue

    All parties involved in antitrust suits claiming Allergan Inc. delayed the launch of generic versions of its dry-eye medication Restasis — in part by transferring patents to a Native American tribe — agreed Thursday that the Judicial Panel on Multidistrict Litigation should consolidate the cases, but they differed on the venue when they pitched Texas, California and New York as options.

  2. January 08, 2018

    Restasis Antitrust Suits Paused For MDL Panel Review

    A Texas federal court on Friday stayed a series of lawsuits accusing Allergan PLC of violating antitrust laws to keep generics for the dry-eye medication Restasis off the market, until the Judicial Panel on Multidistrict Litigation decides whether the cases should be combined.